Enabling Warp Speed Using the Hypervelocity Innovation Model: A Blue Print for Drug Development in Pandemics

Pharmaceutical R&D is organized around prioritized investments, delivering on assets with the greatest return of investments. Linear sequencing of trials and financial risks are determinants of speed in an enterprise. There is less flexibility in leveraging expertise around priorities that are thrust on the system by external forces. This commentary provides an insight into enabling … Continued

Certara Announces Appointment of President of its Software Division

PRINCETON, N.J.—September 17, 2020. Certara, the global leader in biosimulation, today announced the appointment of Leif E. Pedersen as president of its software division, reporting to Chief Executive Officer William F. Feehery, PhD. Mr. Pedersen is a seasoned software industry executive with more than 25 years of experience across a range of software categories. He … Continued

Certara Announces Changes to its Board of Directors

PRINCETON, N.J.—September 1, 2020.  Certara, the global leader in biosimulation, today announced changes to its board of directors, which took effect August 26, 2020.  After successfully transitioning the leadership of Certara to Chief Executive Officer William Feehery, Edmundo Muniz has decided to step down from the board.  William Klitgaard, who has served on the board … Continued

Clinical trials of disease stages in COVID 19: complicated and often misinterpreted

As of July 28, 2020, 1840 clinical trials were registered globally, with 1001 clinical trials recruiting patients for COVID-19 management.1 Despite this large number, only 30 trials have been published as peer-reviewed or preprint publications.2 Media reports and prepublications on medRxiv and bioRxiv represent the most frequent mechanism for data sharing, with wide public reach and usually with little detail. However, … Continued

Accelerating Clinical Evaluation of Repurposed Combination Therapies for COVID-19

As the global COVID-19 pandemic continues, unabated and clinical trials demonstrate limited effective pharmaceutical interventions, there is a pressing need to accelerate treatment evaluations. Among options for accelerated development is the evaluation of drug combinations in the absence of prior monotherapy data. This approach is appealing for a number of reasons. First, combining two or … Continued

3 of 9
Back to top
Powered by Translations.com GlobalLink OneLink Software